Merck Non-GAAP EPS of $2.49 beats by $0.40, revenue of $18.09B beats by $760M (MRK:NYSE)

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

Merck reported $18.1B in Q3 revenue, beating estimates, and raised 2026 sales guidance. The company is investing in its pipeline to offset Keytruda's patent expiry, with positive clinical data supporting its strategy. Keytruda QLEX and Winrevair saw strong sales growth.

Merck (MRK) reported Q3 2026 earnings of $2.49 per share on $18.1B revenue, beating estimates. Sales grew 5%, driven by new product launches and strong oncology performance. KEYTRUDA sales reached $8.6B. Merck raised full-year guidance to $66.8B-$67.3B revenue and $2.77-$2.82 EPS.

Merck (MRK) reported Q3 2026 earnings of $2.49 per share, beating estimates, and raised its 2026 EPS guidance to $2.77-$2.82. Revenue was $18.09B, also beating expectations. Keytruda sales grew 6% to $8.6B. Eli Lilly (LLY) and Johnson & Johnson (JNJ) also saw stock gains. MRK is up 43% YTD, LLY 29%, and JNJ 35%.

Merck reported Q3 2026 sales of $18.1B, up 5%, and adjusted earnings of $2.49/share, beating estimates. The company raised its full-year sales forecast to $66.8B-$67.3B. Keytruda (Qlex) sales were $830M, the highest since launch. Winrevair sales rose 93% to $694M. Animal health sales increased 4% to $1.7B.

Merck & Co. reported Q3 revenue growth of 5% to $18.1B, driven by new products and strong performance in oncology and animal health. The company raised its 2026 guidance midpoint but expects moderate growth in 2027 due to over $2B in generic and LOE headwinds, along with ongoing investments.